Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Vaccine composition and preparation method against swine mycoplasma pneumonia and infectious pleuropneumonia

A technology of mycoplasma pneumonia and vaccine composition, which is applied in the direction of bacterial antigen components, antibody medical components, antibacterial drugs, etc., and can solve the problem of dual combination vaccine and drug prevention and control costs that can simultaneously prevent and treat mycoplasma pneumonia and porcine infectious pleuropneumonia increase, economic loss of aquaculture and other issues, to achieve the effect of low immunization cost, strong practicability, and small side effects

Active Publication Date: 2016-08-17
PU LIKE BIO ENG
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The death of pigs caused by the disease, slow growth, reduced feed remuneration and increased cost of drug control have caused serious economic losses to the breeding industry around the world
[0005] However, so far, there is no dual combination vaccine capable of simultaneously preventing and treating mycoplasma pneumonia and porcine infectious pleuropneumonia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccine composition and preparation method against swine mycoplasma pneumonia and infectious pleuropneumonia
  • Vaccine composition and preparation method against swine mycoplasma pneumonia and infectious pleuropneumonia
  • Vaccine composition and preparation method against swine mycoplasma pneumonia and infectious pleuropneumonia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Example 1: Isolation and identification of Mycoplasma hyopneumoniae HN0613

[0048] 1. Materials and methods

[0049] (1) Materials

[0050] ① source of disease material

[0051] In 2006, 16 suspected lungs with mycoplasma swine pneumonia were collected from various places in Henan Province.

[0052] ② Culture medium

[0053] Mycoplasma hyopneumoniae Friis medium was purchased from BD Company; pig serum was purchased from GIBCO Company; phenol red indicator was purchased from American AMRESCO Company.

[0054] ③ Reagent

[0055] Biochemical reagents and chemical reagents were purchased from Sinopharm Chemical Reagent Co., Ltd.

[0056] Bacterial Genomic DNA Extraction Kit was purchased from TIANGEN Company, and Dieter's Staining Kit was purchased from Chongqing Pangtong Medical Instrument Co., Ltd. Biochemical identification reagents were purchased from Hangzhou Tianhe Microbiological Reagent Co., Ltd. ④ Negative and positive serum

[0057] Rabbit anti-Mycoplasm...

Embodiment 2

[0093] Embodiment 2: Identification of the isolation of serum type 1 LC strain, type 5 YC strain, and type 7 YS strain

[0094] 1. Materials and Methods

[0095] (1) Disease materials to be tested

[0096] The disease materials of pigs with suspected pleuropneumonia were collected from 10 pig farms in Henan, Hubei and other provinces and cities.

[0097] (2) PCR primer sequence

[0098] PF-5'CCGACTTTTAAATCCGT3', PR-5'GAACAGTTGTTCGCTAA3'

[0099] (3) Mice

[0100] Bought from Animal Experiment Center of Henan Province.

[0101] (4) Isolation and purification of pathogenic bacteria and liquid culture

[0102] Aseptically take lungs, throat tonsils and other tissues of dying pigs, inoculate them on TSA (containing 1wt% NAD) agar medium, place in 10% CO 2 After culturing at 37°C for 24-36 hours, a typical single colony was selected for purification. The purified single colonies were selected and inoculated in TSB (containing 1wt% NAD) liquid culture medium, and cultured on ...

Embodiment 3

[0128] Example 3: Preparation of Mycoplasma hyopneumoniae antigen and Actinobacillus pleuropneumoniae antigen

[0129] 1. Source of bacteria (virus) strains

[0130] The selected Actinobacillus pleuropneumoniae strains are: the preservation number of the serum type 1 LC strain is CCTCC M2011458; the preservation number of the serum type 5 YC strain is CCTCC M2011459; the preservation number of the serum type 7 YS strain is CCTCC M2011460. The date of deposit is December 9, 2011.

[0131] The selected Mycoplasma hyopneumoniae is HN0613, and the preservation number is CCTCC No. M2012230. The date of deposit is June 13, 2012.

[0132] 2. Preparation and inspection of vaccine semi-finished products

[0133] (1) Preparation of seeds for production

[0134] ① Actinobacillus pleuropneumoniae:

[0135] Propagation of primary seeds

[0136] Streak and inoculate LC, YC, and YS strains of freeze-dried strains on TSA (soybean casein agar) plates respectively, in 5-10% CO 2 Cultiv...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a vaccine composition against swine mycoplasma pneumonia and infectious pleuropneumonia and a preparation method thereof. The vaccine composition contains Mycoplasma hyopneumoniae antigen and Actinobacillus pleuropneumoniae antigen, has simple immunization procedures, can produce antibodies, and has protection against viruses at the same time, and can effectively prevent and treat Mycoplasma pneumoniae pneumonia and porcine infectious pleuropneumonia. The immune effect of the vaccine composition is at least equal to the effect of separate injection of single vaccine, less side effects, high serum antibody titer, long immunization period, less time-consuming, less labor, and less damage to pigs. The vaccine composition has simple production process, low immunization cost and strong practicability.

Description

technical field [0001] The invention belongs to the technical field of livestock biopharmaceuticals, and relates to a dual multivalent vaccine composition against swine mycoplasma pneumonia and infectious pleuropneumonia and a preparation method thereof. Background technique [0002] Swine asthma, also known as Mycoplasma pneumoniae of swine (MPS) or Swine Enzootic Pneumonia (SEP), is a contact chronic respiratory infectious disease caused by Mycoplasma hyopneumoniae. Prevalent throughout the world. The diseased pigs mainly showed cough and wheezing, growth retardation, low feed conversion rate, and normal body temperature. During anatomy, the main lesions were in the lungs, especially in the heart lobe, middle lobe, and apical lobe of the two lungs, which were characterized by pancreatoid changes and fleshy changes. High morbidity and low mortality. Studies in recent years have found that Mycoplasma hyopneumoniae is mixed with porcine reproductive and respiratory syndrom...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/02A61K39/295A61K39/102A61P31/04A61P31/14A61P31/22A61P31/20A61P31/16
Inventor 张许科孙进忠白朝勇
Owner PU LIKE BIO ENG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products